Eczema is a chronic skin condition that causes inflammation, redness, and itching. It affects approximately 1 in 10 people during their lifetime, making it a prevalent dermatological issue. This high prevalence drives the demand for advanced eczema therapeutic products, including innovative biologics and small-molecule drugs. The growing focus on personalized medicine and targeted therapies is accelerating the development of eczema drug candidates. With increasing investments in research and clinical trials, the pipeline is expected to grow rapidly in the coming years, offering more effective and long-lasting treatment options for patients worldwide.
Major companies involved in the eczema pipeline drugs market include Pfizer, Eli Lilly and Company, and others.
Leading drugs currently in the pipeline include Ruxolitinib Cream, Lebrikizumab, APG777, and others.
Rising disease prevalence, increased investment in advanced therapies like biologics, and a stronger focus on developing targeted treatments are driving significant growth in the eczema drug pipeline.
The Eczema Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into eczema therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for eczema. The eczema report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The eczema pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with eczema treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to eczema.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Eczema, also known as atopic dermatitis, is a chronic skin condition characterized by inflammation, redness, dryness, and itching. It occurs due to a combination of genetic and environmental factors that disrupt the skin barrier, making it more sensitive to irritants. Triggers include allergens, stress, weather changes, and harsh soaps, leading to flare-ups and persistent discomfort.
Eczema treatments focus on managing symptoms and preventing flare-ups. Moisturizers help to maintain skin hydration while topical corticosteroids reduce inflammation. Antihistamines relieve itching, and immunomodulators may be used for severe cases. Lifestyle adjustments, such as avoiding triggers and using gentle skincare products, are crucial. In some cases, phototherapy or advanced biologic medications may be recommended for long-term symptom control.
Eczema affects approximately 1 in 10 people globally. In the United States, around 9.6 million children under 18 years have eczema, with one-third experiencing moderate to severe cases. In the United Kingdom, one in five children and one in ten adults are affected. In Japan, 10% to 20% of children have eczema, while India reports a prevalence of 2.7% to 3.6% among children.
This section of the report covers the analysis of eczema drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total eczema clinical trials.
The drug molecule categories covered under the eczema pipeline analysis include biologics, small molecules, topical corticosteroids, phosphodiesterase-4 (PDE4) inhibitors, and immunomodulators. The eczema report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for eczema.
The EMR report for the eczema drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed eczema therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in eczema clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for eczema. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of eczema drug candidates.
Ruxolitinib Cream (Opzelura), sponsored by Incyte Corporation, is currently being evaluated in a Phase IV clinical trial to assess its effects on sleep disturbances in adults with atopic dermatitis. This selective JAK1/JAK2 inhibitor is already approved in the United States for treating mild to moderate atopic dermatitis in patients aged 12 and older when other therapies are ineffective or unsuitable.
Lebrikizumab (LY3650150), sponsored by Eli Lilly and Company, is currently being evaluated in a Phase III study to assess its long-term safety and efficacy in participants aged 6 months to <18 years with moderate-to-severe atopic dermatitis (eczema). This monoclonal antibody targets IL-13, a key driver of eczema inflammation, helping to reduce itching, dryness, and irritation.
APG777, sponsored by Apogee Therapeutics, Inc., is being evaluated in a Phase II study to assess its safety and efficacy in moderate-to-severe atopic dermatitis (AD). It is a subcutaneous, half-life extended monoclonal antibody targeting IL-13, demonstrating equal or superior potency to lebrikizumab in blocking IL-13 signaling. The study will enroll 391 participants over 106 weeks.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Eczema Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for eczema. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into eczema collaborations, regulatory environments, and potential growth opportunities.
Atopic Dermatitis Market Report and Forecast
Global Atopic Dermatitis Treatment Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share